1 reports of this reaction
0.9% of all NAPROXEN AND ESOMEPRAZOLE MAGNESIUM reports
#12 most reported adverse reaction
ARRHYTHMIA is the #12 most commonly reported adverse reaction for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, manufactured by Ajanta Pharma USA Inc.. There are 1 FDA adverse event reports linking NAPROXEN AND ESOMEPRAZOLE MAGNESIUM to ARRHYTHMIA. This represents approximately 0.9% of all 107 adverse event reports for this drug.
Patients taking NAPROXEN AND ESOMEPRAZOLE MAGNESIUM who experience arrhythmia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ARRHYTHMIA is a less commonly reported adverse event for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, but still significant enough to appear in the safety profile.
In addition to arrhythmia, the following adverse reactions have been reported for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM:
The following drugs have also been linked to arrhythmia in FDA adverse event reports:
ARRHYTHMIA has been reported as an adverse event in 1 FDA reports for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
ARRHYTHMIA accounts for approximately 0.9% of all adverse event reports for NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, making it a notable side effect.
If you experience arrhythmia while taking NAPROXEN AND ESOMEPRAZOLE MAGNESIUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.